Glycoproteomics-based Liquid-biopsy LDT Development Service for Renal Cell Carcinoma
Renal Cell Carcinoma
Renal Cell Carcinoma (RCC) is a heterogeneous and often aggressive form of kidney cancer that poses significant challenges in terms of diagnosis and treatment. The efficacy of various agents approved remains limited in advanced RCC patients. As a result, gaining a comprehensive understanding of the molecular alterations underlying the development of RCC is imperative for devising effective therapeutic strategies.
Notably, aberrations in glycoproteins have been implicated in the pathogenesis of RCC. The identification of dysregulated glycoproteins and glycosylation events, along with their associated signaling pathways, holds the potential to offer targeted treatment options for RCC. With the advancements in mass spectrometry (MS)-based glycoproteomics, a comprehensive characterization would provide a platform for investigating the specific roles of protein glycosylation in disease development and progression.
Glycoproteomics-based Liquid-biopsy LDT Development for RCC at Creative Biolabs
Our dedicated team of experts at Creative Biolabs leverages the power of glycoproteomics to develop state-of-the-art liquid-biopsy laboratory-developed test (LDT) services for RCC. We have successfully established a platform for the identification and quantification of intact N-linked glycopeptides based on a bottom-up approach, as intact glycopeptides analysis provides more accurate information about glycosylation sites and heterogeneity of glycan structures.
Quality and accuracy of results are ensured through rigorous quality control measures at the glycan, peptide, and glycopeptide levels. Integrated approaches to data analysis have enhanced our ability to unravel the functional implications of glycoproteomic data within a broader biological context in RCC.
Fig.1 Glycoproteomics-based LDT for intact N-linked glycopeptides analysis.
Highlights
-
Hydrophilic interaction chromatography (HILIC)
Unbiased, highly specific, and high-throughput enrichment.
|
Precise measurements of accurate masses (<5-10 ppm) for both precursor and product ions;
High-performance informatics solutions based on powerful AI algorithms.
|
In-depth pathway enrichment analysis using well-established databases;
Comprehensive integration with other available omics datasets of RCC;
Strict statistical analysis with p-values and false discovery rate (FDR).
|
-
Professional technical team
Our experts have extensively specialized in the field of glycoproteomics.
|
Published Data
Technology: Glycoproteomic analysis
Journal: Cell Reports
Published: 2023
Results: Altered glycosylation enzymes and corresponding protein glycosylation are observed. The relation of glycoproteomic features to genomic, transcriptomic, and proteomic changes shows the role of glycosylation in ccRCC development with potential for therapeutic interventions.
Fig.2 Altered glycosylation in ccRCC.1
At Creative Biolabs, we are committed to advancing diagnostic solutions for complex diseases like RCC. Our liquid biopsy LDT services based on glycoproteomics offer a promising avenue for enhancing RCC diagnosis and monitoring. Please free to contact us or submit an inquiry directly. Our team of experts is readily available to address any inquiries.
Reference
-
Lih, T. Mamie, et al. "Integrated glycoproteomic characterization of clear cell renal cell carcinoma." Cell reports 42.5 (2023).
For Research Use Only.
Related Services:
- NASH
- NSCLC
- Pancreas Carcinoma
- Nasopharyngeal Carcinoma
- HCC
- Advanced Adenoma
- Colorectal Cancer
- Prostate Cancer
